Tumor-activated monocytes promote expansion of IL-17-producing CD8 + T cells in hepatocellular carcinoma patients

Journal of Immunology

Volumn 185, Issue 3, 2010, Pages 1544-1549

  Kuang, Dong Ming ^a,b   Peng, Chen ^b   Zhao, Qiyi ^b   Wu, Yan ^b   Zhu, Ling Yan ^b   Wang, Jianen ^b   Yin, Xiao Yu ^b   Li, Lian ^b   Zheng, Limin ^a,b  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD68 ANTIGEN; GAMMA INTERFERON; GRANZYME B; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 6; PERFORIN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL EXPANSION; CELL INVASION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; LYMPHOCYTE PROLIFERATION; MONOCYTE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; BIOSYNTHESIS; CANCER INVASION; CELL PROLIFERATION; CELL STRAIN HEPG2; COCULTURE; CULTURE MEDIUM; IMMUNOLOGY; LIVER TUMOR; MACROPHAGE ACTIVATION; METABOLISM; PATHOLOGY; TUMOR CELL CULTURE;

CARCINOMA, HEPATOCELLULAR; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; COCULTURE TECHNIQUES; CULTURE MEDIA, CONDITIONED; HEP G2 CELLS; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-17; LIVER NEOPLASMS; MACROPHAGE ACTIVATION; MONOCYTES; NEOPLASM INVASIVENESS; TUMOR CELLS, CULTURED;

EID: 77956397098     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0904094     Document Type: Article

References (35)

1. Mueller, M. M., and N. E. Fusenig. 2004. Friends or foes: bipolar effects of the tumour stroma in cancer. Nat. Rev. Cancer 4: 839-849.
2. Tlsty, T. D., and L. M. Coussens. 2006. Tumor stroma and regulation of cancer development. Annu. Rev. Pathol. 1: 119-150.
3. Ahmed, F., J. C. Steele, J. M. Herbert, N. M. Steven, and R. Bicknell. 2008. Tumor stroma as a target in cancer. Curr. Cancer Drug Targets 8: 447-453.
4. Zou, W., and L. Chen. 2008. Inhibitory B7-family molecules in the tumour microenvironment. Nat. Rev. Immunol. 8: 467-477.
5. Budhu, A., M. Forgues, Q. H. Ye, H. L. Jia, P. He, K. A. Zanetti, U. S. Kammula, Y. Chen, L. X. Qin, Z. Y. Tang, and X. W. Wang. 2006. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 10: 99-111.
6. Kuang, D. M., Q. Zhao, C. Peng, J. Xu, J. P. Zhang, C. Wu, and L. Zheng. 2009. Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J. Exp. Med. 206: 1327-1337.
7. Kuang, D. M., C. Peng, Q. Zhao, Y. Wu, M. S. Chen, and L. Zheng. 2010. Activated monocytes in peritumoral stroma of hepatocellular carcinoma promote expansion of memory T helper 17 cells. Hepatology 51: 154-164.
8. + IL-17-producing T cells in ovarian cancer. Proc. Natl. Acad. Sci. USA 105: 15505-15510.
9. Zhang, J. P., J. Yan, J. Xu, X. H. Pang, M. S. Chen, L. Li, C. Wu, S. P. Li, and L. Zheng. 2009. Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J. Hepatol. 50: 980-989.
10. Wang, L., T. Yi, M. Kortylewski, D. M. Pardoll, D. Zeng, and H. Yu. 2009. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J. Exp. Med. 206: 1457-1464.
11. Kryczek, I., M. Banerjee, P. Cheng, L. Vatan, W. Szeliga, S. Wei, E. Huang, E. Finlayson, D. Simeone, T. H. Welling, et al. 2009. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 114: 1141-1149.
12. Kuang, D. M., Q. Zhao, J. Xu, J. P. Yun, C. Wu, and L. Zheng. 2008. Tumor-educated tolerogenic dendritic cells induce CD3epsilon down-regulation and apoptosis of T cells through oxygen-dependent pathways. J. Immunol. 181: 3089-3098.
13. Cheng, J., D. H. Huo, D. M. Kuang, J. Yang, L. Zheng, and S. M. Zhuang. 2007. Human macrophages promote the motility and invasiveness of osteopontin-knockdown tumor cells. Cancer Res. 67: 5141-5147.
14. Kuang, D. M., Y. Wu, N. Chen, J. Cheng, S. M. Zhuang, and L. Zheng. 2007. Tumor-derived hyaluronan induces formation of immunosuppressive macrophages through transient early activation of monocytes. Blood 110: 587-595.
15. Uphoff, C. C., and H. G. Drexler. 2002. Detection of mycoplasma in leukemia-lymphoma cell lines using polymerase chain reaction. Leukemia 16: 289-293.
16. Dong, C. 2008. TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat. Rev. Immunol. 8: 337-348.
17. H-17 responses. Nat. Immunol. 9: 650-657.
18. H-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat. Nat. Immunol. 9: 641-649.
19. Zhang, F., G. Meng, and W. Strober. 2008. Interactions among the transcription factors Runx1, RORgammat and Foxp3 regulate the differentiation of interleukin 17-producing T cells. Nat. Immunol. 9: 1297-1306.
20. Klotz, L., S. Burgdorf, I. Dani, K. Saijo, J. Flossdorf, S. Hucke, J. Alferink, N. Nowak, and M. Beyer, G. Mayer et al. 2009. The nuclear receptor PPAR gamma selectively inhibits Th17 differentiation in a T cell-intrinsic fashion and suppresses CNS autoimmunity. J. Exp. Med. 206: 2079-2089.
21. Moser, B., and P. Loetscher. 2001. Lymphocyte traffic control by chemokines. Nat. Immunol. 2: 123-128.
22. Kolls, J. K., and A. Lindén. 2004. Interleukin-17 family members and inflammation. Immunity 21: 467-476.
23. Ma, H. L., S. Liang, J. Li, L. Napierata, T. Brown, S. Benoit, M. Senices, D. Gill, K. Dunussi-Joannopoulos, M. Collins, et al. 2008. IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. J. Clin. Invest. 118: 597-607.
24. Kim, S., H. Takahashi, W. W. Lin, P. Descargues, S. Grivennikov, Y. Kim, J. L. Luo, and M. Karin. 2009. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 457: 102-106.
25. Langowski, J. L., R. A. Kastelein, and M. Oft. 2007. Swords into plowshares: IL-23 repurposes tumor immune surveillance. Trends Immunol. 28: 207-212.
26. Rabinovich, G. A., D. Gabrilovich, and E. M. Sotomayor. 2007. Immunosuppressive strategies that are mediated by tumor cells. Annu. Rev. Immunol. 25: 267-296.
27. Yen, H. R., T. J. Harris, S. Wada, J. F. Grosso, D. Getnet, M. V. Goldberg, K. L. Liang, T. C. Bruno, K. J. Pyle, S. L. Chan, et al. 2009. Tc17 CD8 T cells: functional plasticity and subset diversity. J. Immunol. 183: 7161-7168.
28. Annunziato, F., L. Cosmi, V. Santarlasci, L. Maggi, F. Liotta, B. Mazzinghi, E. Parente, L. Filì, S. Ferri, F. Frosali, et al. 2007. Phenotypic and functional features of human Th17 cells. J. Exp. Med. 204: 1849-1861.
29. + T cells producing IL-17. J. Immunol. 182: 1794-1798.
30. + T cells. J. Exp. Med. 205: 1019-1027.
31. Hamada, H., Mde. L. Garcia-Hernandez, J. B. Reome, S. K. Misra, T. M. Strutt, K. K. McKinstry, A. M. Cooper, S. L. Swain, and R. W. Dutton. 2009. Tc17, a unique subset of CD8 T cells that can protect against lethal influenza challenge. J. Immunol. 182: 3469-3481.
32. Mantovani, A., P. Allavena, A. Sica, and F. Balkwill. 2008. Cancer-related inflammation. Nature 454: 436-444.
33. H17 cells in tumour immunity and immunotherapy. Nat. Rev. Immunol. 10: 248-256.
34. Guiducci, C., A. P. Vicari, S. Sangaletti, G. Trinchieri, and M. P. Colombo. 2005. Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res. 65: 3437-3446.
35. Murdoch, C., M. Muthana, S. B. Coffelt, and C. E. Lewis. 2008. The role of myeloid cells in the promotion of tumour angiogenesis. Nat. Rev. Cancer 8: 618-631.